FitLife Brands (FTLF) Competitors

FitLife Brands (NASDAQ:FTLF) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

Which has preferable earnings & valuation, FTLF or ORGO?

FitLife Brands has higher earnings, but lower revenue than Organogenesis. Organogenesis is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$64.47M	2.66	$8.98M	$0.84	21.77
Organogenesis	$429.31M	1.39	$860K	-$0.14	-33.54

Does the media prefer FTLF or ORGO?

In the previous week, FitLife Brands had 1 more articles in the media than Organogenesis. MarketBeat recorded 1 mentions for FitLife Brands and 0 mentions for Organogenesis. FitLife Brands' average media sentiment score of 0.90 beat Organogenesis' score of 0.00 indicating that FitLife Brands is being referred to more favorably in the media.

Company	Overall Sentiment
FitLife Brands	Positive
Organogenesis	Neutral

Do insiders and institutionals believe in FTLF or ORGO?

2.3% of FitLife Brands shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 61.4% of FitLife Brands shares are owned by company insiders. Comparatively, 33.0% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Which has more risk & volatility, FTLF or ORGO?

FitLife Brands has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500.

Do analysts rate FTLF or ORGO?

FitLife Brands currently has a consensus target price of $22.00, indicating a potential upside of 20.28%. Organogenesis has a consensus target price of $7.50, indicating a potential upside of 59.74%. Given Organogenesis' higher possible upside, analysts clearly believe Organogenesis is more favorable than FitLife Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Organogenesis	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Is FTLF or ORGO more profitable?

FitLife Brands has a net margin of 12.63% compared to Organogenesis' net margin of -1.92%. FitLife Brands' return on equity of 21.70% beat Organogenesis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FitLife Brands	12.63%	21.70%	13.45%
Organogenesis	-1.92%	-0.37%	-0.20%

Summary

FitLife Brands beats Organogenesis on 12 of the 16 factors compared between the two stocks.